Related Experiment Video

Updated: Jul 16, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

753

Why is There Still Debate About Recommending DPYD-Testing Before Fluoropyrimidine Treatment?

Ingolf Cascorbi1

  • 1Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany.

Clinical Pharmacology and Therapeutics
|September 15, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform
08:37

Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform

Published on: October 22, 2021

3.0K

Related Experiment Videos

Last Updated: Jul 16, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

753
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform
08:37

Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform

Published on: October 22, 2021

3.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2026

Deciphering the Relative Contribution of CYP3A4 Versus P-Glycoprotein for the Shared Substrate Cyclosporine-Commentary on Lown et al.

Clinical pharmacology and therapeutics·2025

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon.

Pharmacogenomics·2024

Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity.

eLife·2024

Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol.

Expert opinion on drug metabolism & toxicology·2024

Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.

Clinical pharmacology and therapeutics·2024

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid-Related Adverse Events Following Surgery for Breast Cancer.

Clinical pharmacology and therapeutics·2026

Characteristics of Severe and Typical Agranulocytosis Induced by Antithyroid Drugs.

Clinical pharmacology and therapeutics·2026

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug-Induced Liver Injury: A Multicentric Propensity Scores Matched Study.

Clinical pharmacology and therapeutics·2026

Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study.

Clinical pharmacology and therapeutics·2026

Tramadol Co-Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control.

Clinical pharmacology and therapeutics·2026

Translational Paradox of Triplet Repeat Expansion Disorders: Synthesizing Clinical Trial Failures to Guide Future Therapeutics.

Clinical pharmacology and therapeutics·2026

Small intestine melanosis caused by clofazimine: A case report.

Medicine·2026

A retrospective comparative study of CT and MRI findings of different types of pancreatic serous cystic neoplasms: Correlation with histopathology.

Medicine·2026

Evaluating the relationship between C-peptide levels and insulin resistance in patients with and without diabetic complications.

Medicine·2026

Relative colon wall attenuation - distinguishing ischemia from other colon wall changes.

BMC medical imaging·2026

Transition from preclinical obesity to clinical obesity among US adults: incidences and risk factors.

International journal of obesity (2005)·2026

Clinicopathological factors associated with HER2 FISH positivity in HER2 IHC 2 + breast cancer: a multicenter study.

Scientific reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us